Skip To Main Content
Luis Puig on Muck Rack

Luis Puig

As seen in: Wiley Online Library, American Journal of Clinical Dermatology, Oxford Academic, Taylor & Francis Online, JAMA (The Journal of the American Medical Association), The Lancet, Dialnet - Universidad de La Rioja, Journal of The American Academy of Dermatology (JAAD), EMJ- European Medical Journal, SKIN The Journal of Cutaneous Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Luis

Contact Luis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Psoriasis y su relación con el síndrome metabólico

|
By Ángela María Londoño, Cesar Gonzalez, César González, Luis Puig, Castro Franco
| Dialnet - Universidad de La Rioja
Ayuda Buscar en la ayuda Buscar en la ayuda Psoriasis y su relación con el síndrome metabólico Ángela Londoño [1] ; César González [2] ; Luis Castro [3] ; Lluís Puig [4] [1] Universidad Pontificia Bolivariana [2] Universidad El Bosque [3] Universidad Militar Nueva Granada [4] Hospital de la Santa Creu i Sant Pau Localización: Revista Colombiana de Reumatología, ISSN-e 0121-8123, Vol. 20, Nº. 4, 2013, págs.
Open in Who Shared Issue with article?

Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy

|
By Luis Puig
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Mullard, A Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease Nat Rev Drug Discov. 2025; 24:321 2. Knight, B ∙ Tammara, B ∙ Modi, NB ∙ et al. Translational pharmacokinetics of icotrokinra, a targeted oral peptide that selectively blocks interleukin-23 receptor and inhibits signaling Dermatol Ther (Heidelb). 2025; 15:2495-2520 3. Gooderham MJ, Lain E, Bissonette R, et al.
Open in Who Shared Issue with article?

Journal of the European Academy of Dermatology and Venereology | Wiley Online Library

|
By Kim A. Papp, Temerty Faculty, Luis Puig, Jennifer Beecker
| Wiley Online Library Verified
Why was the study undertaken? Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancer and often result in immune-mediated adverse events, including psoriasis. This position statement provides guidance on the systemic treatment of ICI-mediated psoriasis. When considering the use of systemic agents for the treatment of psoriasis, clinicians are concerned about the possibility of interfering with ICI effectiveness. What does this study add?
Open in Who Shared Issue with article?
See all 13 articles